Intercept Pharmaceuticals

Overview

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company based in Morristown, New Jersey, offering innovative therapeutic solutions for progressive non-viral liver diseases. Established in 2002, the organization is recognized for its research and development of treatments targeting chronic conditions such as primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).

The company's flagship product, Ocaliva (obeticholic acid), is a first-in-class FXR agonist approved for adult PBC treatment and additionally being developed for diverse liver-related conditions. Intercept continues to expand its therapeutic pipeline with candidates like INT-787 for severe alcohol-associated hepatitis and bezafibrate for potential PBC treatment. Operating as a subsidiary of Alfasigma S.p.A. since 2023, Intercept markets its products across the United States, Europe, and Canada, underscoring its commitment to patient-focused innovation and collaboration within the biopharmaceutical industry.

Basic Information

Contact Details

• Phone: +1 646-747-1000
• Website: interceptpharma.com
• LinkedIn: linkedin.com/company/intercept-pharmaceuticals

Key Focus Areas & Initiatives

• Nonviral liver diseases
• Rare diseases
• Biotechnology
• Innovation in healthcare
• Pharmaceutical manufacturing
• Clinical research & trials
• Liver disease pipeline & research
• Development of FXR agonists
• Patient-centered therapies
• Therapeutic pipeline for rare liver diseases
• FDA-approved therapies for chronic illness
• Liver fibrosis & cirrhosis treatments
• Autoimmune liver disease solutions
• Therapeutic innovations targeting PBC and NASH
• Patient support and advocacy

Technologies Used

• AI
• Amazon AWS
• Amazon CloudFront
• Amazon SES
• Drupal
• Google Analytics
• Google Tag Manager
• Mobile Friendly
• OneTrust
• Outlook
• Remote
• Route 53
• Salesforce
• UltraDns
• Vimeo
• WP Engine
• WordPress.org

Affiliated Organizations & Regional Branches

• Alfasigma